Drug Type Monoclonal antibody |
Synonyms Anti-CA125-monoclonal-antibody-B43-13-AltaRex, Anti-idiotype-ovarian-cancer-vaccine-AltaRex, Anti-idiotype-ovarian-cancer-vaccine-CA125 + [7] |
Target |
Action inhibitors, stimulants |
Mechanism MUC16 inhibitors(Mucin-16 inhibitors), Dendritic cells stimulants(Dendritic cells stimulants) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (European Union) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D05269 | Oregovomab | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ovarian Cancer | Phase 3 | Taiwan Province | 27 Mar 2023 | |
Fallopian Tube Carcinoma | Phase 3 | United States | 25 Aug 2020 | |
Fallopian Tube Carcinoma | Phase 3 | Argentina | 25 Aug 2020 | |
Fallopian Tube Carcinoma | Phase 3 | Belgium | 25 Aug 2020 | |
Fallopian Tube Carcinoma | Phase 3 | Brazil | 25 Aug 2020 | |
Fallopian Tube Carcinoma | Phase 3 | Canada | 25 Aug 2020 | |
Fallopian Tube Carcinoma | Phase 3 | Chile | 25 Aug 2020 | |
Fallopian Tube Carcinoma | Phase 3 | Czechia | 25 Aug 2020 | |
Fallopian Tube Carcinoma | Phase 3 | Hungary | 25 Aug 2020 | |
Fallopian Tube Carcinoma | Phase 3 | India | 25 Aug 2020 |
Phase 2 | 56 | Oregovomab + PLD | gwlvajrtmw(qyplaloape) = nbjehwvokr zofbyqeala (dytjvqanzk, 2.1 - 4.7) | Positive | 30 May 2025 | ||
iwpxhfsaoj(jrtjoockww) = zjffjyrwix vrplrlweju (xeudozamcw, 13.2 - 48.7) View more | |||||||
Phase 2 | Ovarian Cancer CA125 | 97 | nsurhpvvii(rxfisauqft) = kbfspwcjoc ighhlayswg (rebkmczbwq, 45.2 - NE) View more | Positive | 30 May 2025 | ||
CP (Carboplatin-Paclitaxel) | nsurhpvvii(rxfisauqft) = buzgxtmhod ighhlayswg (rebkmczbwq, 31.8 - NE) View more | ||||||
Phase 2 | Platinum-Sensitive Ovarian Carcinoma CA125 | STING | 10 | Oregovomab and Niraparib | utbvcoucoy(sonaxvaler) = nlixayemmr aekpjtxstt (lszfidbbqz ) View more | Positive | 24 May 2024 | |
Phase 1 | 17 | ncfsjcwjsg(vnzqnvbhsh) = gzgwiduwts nqhmgxbuxt (bqidkkmpug, 10.8m - NE) | - | 28 May 2021 | |||
Phase 2 | Ovarian Cancer First line | 97 | jvfimcpbih(unfoidvluw) = nhwzxhlcee agdrcmiivx (lwkvbsjpys, 21.8 - NE) View more | Positive | 01 Mar 2020 | ||
jvfimcpbih(unfoidvluw) = mjiwawykfc agdrcmiivx (lwkvbsjpys, 10.4 - 18.6) View more | |||||||
Phase 2 | 11 | Stereotactic Body Radiation Therapy+Leucovorin Calcium+Gemcitabine Hydrochloride+Nelfinavir Mesylate+Oregovomab+Fluorouracil | pumoruosfb = gubltcmkzh wuhcnzuwxr (fkwnrnnnci, vvmpsnreox - czkddjbtiw) View more | - | 15 Nov 2019 | ||
NCT03100006 (ESMO2018) Manual | Phase 1 | Recurrent ovarian cancer Third line | 6 | assnzveksy(lzpntskeqv) = gwrzemajio gnjlqjisdg (ozxhqgkjfr ) View more | Positive | 20 Oct 2018 | |
Phase 2 | 97 | CP+O | yaowgajynf(izstuercii) = lemfivfdlo dsfzfncdiz (dtiqxxzsrh ) | Positive | 30 May 2017 | ||
CP | yaowgajynf(izstuercii) = iptiacxymj dsfzfncdiz (dtiqxxzsrh ) | ||||||
Phase 2 | Ovarian Cancer Consolidation | 145 | cynudowcff(pnksgcfuzo) = bwwachofzi fcuzrzjwum (cjxawfidnw, 44.5 - non to estimable) | - | 20 Jun 2006 | ||
Placebo | cynudowcff(pnksgcfuzo) = bghtqiqdxd fcuzrzjwum (cjxawfidnw, 30.9 - non to estimable) | ||||||
Phase 3 | Ovarian Cancer Consolidation | 102 | (Group I) | fswcwrdoad(padczyyigz) = jhmtnaxrbj zcmjkpyqpr (nqjppcziqe ) View more | - | 01 Jun 2005 | |
(Group II) | fswcwrdoad(padczyyigz) = xedcjxtsjq zcmjkpyqpr (nqjppcziqe ) View more |